Hidefumi Kinoshita

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.

David F. Jarrard, Hidefumi Kinoshita, Yan Shi et al. · PubMed · 1998 · 236 citations

Androgen Receptor, Epigenetic Change, Genetics +18

Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.

Hidefumi Kinoshita, Y. Shi, Carol Sandefur et al. · PubMed · 2000 · 188 citations

Androgen Receptor, Epigenetic Change, Genetics +16

Formation of 8‐hydroxy‐2′‐deoxyguanosine and 4‐hydroxy‐2‐nonenal‐modified proteins in human renal‐cell carcinoma

Keisei Okamoto, Shinya Toyokuni, Kôji Uchida et al. · International Journal of Cancer · 1994 · 179 citations

Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated Patient

Toru Yoshida, Hidefumi Kinoshita, Takehiko Segawa et al. · Cancer Research · 2005 · 176 citations · Full text